
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is a clinical-stage biotech company with an innovative pipeline, including GRI-0621, a potential treatment for psoriasis and acne, and GRI-0803, a potential treatment for autoimmune disorders like lupus and multiple sclerosis. With a large market potential for lupus and a strong balance sheet and raised funds, GRI Bio's current valuation is attractive, offering significant upside potential. However, risks such as balance sheet/liquidity, product efficacy and regulatory approvals, and market competition should also be considered.
Bears say
GRI Bio is a clinical stage biotech company with two potential drug candidates, GRI-0621 for IPF and GRI-0803 for autoimmune disorders, in its pipeline. However, there are significant market risks due to competition, changing macroeconomic factors, and potential failure of product candidates to demonstrate safety and efficacy in clinical trials. Additionally, the company has no current revenue and a high net loss, which could create balance sheet and liquidity risks in the future. These factors contribute to the negative outlook on GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares